Conversations about the cost and impact of Brexit tend to focus on the UK, but the Brexit-related relocation to Amsterdam and other activities cost the European Medicines Agency (EMA) €59.6 million ($66 million) in 2019, according to the latest tally.
By comparison, EMA spent €15.5 million ($17 million) on Brexit-related expenses in 2018. About 90% of EMA’s budget comes from pharmaceutical industry fees, according to the European Parliament, which compares with about 65% of FDA’s drug budget coming from industry user fees.
The announcement of the Brexit-related budget costs comes as EMA has relocated its headquarters from London to Amsterdam and as EMA is working on a scenario in which the UK will become a third country and no longer will engage as (co)-rapporteur for new marketing authorisation applications via the centralized procedure.
And although the Brexit deadline has been pushed back to 31 January 2020, EMA staff will likely move into their new permanent offices and workspaces in Amsterdam in January 2020, the agency said…